2025-10-19 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data provided. I'll follow the structure you requested, providing key figures, concise analysis, and a final summary.

**Report: Johnson & Johnson (JNJ) Stock Analysis**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research and development, manufacture, and sale of a range of products in the healthcare field.
*   **JNJ Cumulative Return:** 48.79%
*   **VOO Cumulative Return:** 97.05%
*   **Absolute Divergence:** -49.5%
*   **Divergence Range:** Max: 16.6%, Min: -65.5%
*   **Relative Divergence:** 19.5%

**Analysis:** JNJ has significantly underperformed the S&P 500 over the covered period. The relative divergence of 19.5% suggests that JNJ's underperformance is near the lower end of its historical range compared to the S&P 500.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha    | Beta    | Cap(B) |
|------------|---------|--------|----------|---------|--------|
| 2015-2017  | 26.0%  | 66.8%  | -2.0%   | -0.1   | 336.5  |
| 2016-2018  | 14.0%  | 10.7%  | -1.0%   | 0.1    | 310.8  |
| 2017-2019  | 20.0%  | 71.5%  | -2.0%   | 0.4    | 351.3  |
| 2018-2020  | 19.0%  | 79.2%  | -4.0%   | 0.4    | 379.0  |
| 2019-2021  | 33.0%  | 79.2%  | -14.0%  | 0.5    | 412.0  |
| 2020-2022  | 8.0%  | 79.6%  | 9.0%    | 0.4    | 425.4  |
| 2021-2023  | -19.0% | 79.6%  | -20.0%  | 0.3    | 377.5  |
| 2022-2024  | -32.0% | 79.6%  | -53.0%  | 0.3    | 348.3  |
| 2023-2025  | 20.0%  | 79.6%  | -42.0%  | 0.1    | 465.3  |

**Analysis:**

*   **Alpha:** The alpha is highly variable, showing periods of both outperformance and underperformance relative to the market. Recent years show significant negative alpha, suggesting JNJ has been underperforming its benchmark.
*   **Beta:** The beta values are generally low, indicating that JNJ is less volatile than the market. However, the low beta may not be beneficial during bull market periods, contributing to underperformance.
*   **CAGR:** The Compound Annual Growth Rate (CAGR) has fluctuated significantly, with recent periods showing negative growth.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating substantial risk of loss during the observed periods.
*   **Cap:** Market capitalization shows overall growth but has fluctuated, reflecting market conditions and company performance.

**2. Recent Price Action**

*   **Current Price:** 193.22
*   **Previous Close:** 192.12
*   **Change:** 0.57
*   **5-day Moving Average:** 191.65
*   **20-day Moving Average:** 185.98
*   **60-day Moving Average:** 178.46

**Analysis:** The price is above all three moving averages, suggesting a short-term upward trend. The recent increase from the previous close indicates positive momentum.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment)
*   **RSI:** 94.91 (Overbought)
*   **PPO:** 0.1572
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Divergence Change:** 4.3% (Positive - short-term increase)
*   **Expected Return:** -85.1% (Long-term, vs. S&P 500)

**Analysis:**

*   The RSI is very high, indicating overbought conditions and a potential pullback.
*   The MRI suggests low investment risk, contradicting the very high RSI.
*   The recent positive change in relative divergence indicates short-term upward momentum.
*   **The expected return is extremely negative, suggesting significant underperformance relative to the S&P 500 over the long term.** This is a critical concern.
*   The price increase from 192.12 to 193.22 indicates a minor positive change, not a significant surge or drop.

**4. Recent News & Significant Events**

*   **Overall Tone:** The recent news is mixed.
    *   Positive: J&J's Tecvayli-Darzalex combination showing positive results in multiple myeloma trials. Analyst assessment of Q3 earnings.
    *   Neutral: Board of Directors appointment at Diorasis Therapeutics (related to the industry).
    *   General Market: S&P 500 gaining.

**Analysis:** The news regarding the myeloma treatment is a positive catalyst. Analyst opinions after robust Q3 earnings should be considered.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.12 (~Buy)
*   **Opinions:** 23
*   **Target Price:**
    *   Average: 198.03
    *   High: 225.00
    *   Low: 155.00
*   **Recent Rating Changes:** No changes indicated ( → )

**Analysis:** Analyst consensus is positive, with a "Buy" rating and an average target price slightly above the current price. However, the wide range in target prices suggests some uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜         | EPS   | 매출       |
|--------------|-------|------------|
| 2025-07-24   | 2.30  | 23.74 B$   |
| 2025-04-23   | 4.57  | 21.89 B$   |
| 2024-10-23   | 1.12  | 22.47 B$   |
| 2024-07-25   | 1.95  | 22.45 B$   |
| 2025-07-24   | 1.95  | 22.45 B$   |

**Analysis:** Earnings per share (EPS) and revenue have fluctuated over the past few quarters. The most recent EPS is showing an unstable state.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $23.74B    | 67.87%        |
| 2025-03-31 | $21.89B    | 66.40%        |
| 2024-12-31 | $22.52B    | 68.35%        |
| 2024-09-30 | $22.47B    | 69.01%        |
| 2024-06-30 | $22.45B    | 69.40%        |

Capital and Profitability:

| Quarter    | Equity     | ROE     |
|------------|------------|---------|
| 2025-06-30 | $78.47B    | 7.06%   |
| 2025-03-31 | $78.11B    | 14.08%  |
| 2024-12-31 | $71.49B    | 4.80%   |
| 2024-09-30 | $70.16B    | 3.84%   |
| 2024-06-30 | $71.54B    | 6.55%   |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable, showing slight fluctuations.
*   **Profit Margin:** Profit margins are consistently high, indicating strong profitability, but have decreased slightly in the most recent quarter.
*   **Equity:** Equity has generally increased, reflecting the company's growth.
*   **ROE:** Return on Equity (ROE) has fluctuated, with the highest value in 2025-03-31, indicating varying levels of efficiency in generating profits from equity.

**7. Overall Analysis and Summary**

Johnson & Johnson (JNJ) presents a mixed picture. While the company exhibits strong financial fundamentals (high profit margins, stable revenue, and positive analyst ratings), it has significantly underperformed the S&P 500, with a large negative expected return over the long term. Technical indicators show overbought conditions, suggesting a potential pullback.

**Key Considerations:**

*   **Underperformance:** The most significant concern is the substantial underperformance relative to the S&P 500 and the negative expected return.
*   **Overbought:** The high RSI indicates the stock may be overbought in the short term.
*   **Analyst Ratings:** The positive analyst consensus provides some confidence, but the wide range in target prices highlights uncertainty.
*   **News:** The positive news regarding the myeloma treatment is a potential catalyst.
*   **Market Risk Indicator:** Despite the positive recent divergence change, the overbought signal could lead to a correction.

**Recommendation:**

Given the significant underperformance, negative expected return, and overbought conditions, investors should exercise caution. It would be prudent to review the reasons for the underperformance and assess whether the company has a viable strategy to improve its relative performance in the future. A pullback may provide a better entry point.

